Page 28 - 《中国药房》2026年3期
P. 28

专职临床试验药师在抗肿瘤药物早期临床试验管理中的角色定

          位研究
                     Δ


                *
          赵 娟 ,龚 莉,沈 杰,杨辉尧,廖 斌(重庆大学附属肿瘤医院Ⅰ期病房,重庆 400030)
                                                #
          中图分类号  R95      文献标志码  A      文章编号  1001-0408(2026)03-0294-05
          DOI  10.6039/j.issn.1001-0408.2026.03.04

          摘   要  目的  明确专职临床试验药师在抗肿瘤药物早期临床试验管理中的核心角色定位与职能,为其从传统药品管理者向临床
          研究多维度角色转型提供理论依据与实践支撑。方法  结合《药物临床试验质量管理规范(2020版)》等法律法规,基于本院Ⅰ期
          病房临床实践经验,系统梳理专职临床试验药师在抗肿瘤药物早期临床试验中的核心角色与职能,并探讨国内专职临床试验药师
          在角色转型与能力培养中的核心挑战与优化路径。结果与结论  专职临床试验药师在抗肿瘤药物早期临床试验中承担多元角色,
          其核心职能包括在方案设计中提供药学专业支持、对临床试验用药品进行全流程规范化管理、为临床试验受试者/参与者提供用
          药安全保障、对临床试验全程进行质量控制及作为跨学科协作沟通桥梁。当前国内该领域存在专职临床试验药师角色定位不清
          晰、能力培养体系不完善、法规支撑不足等挑战。笔者提出可通过构建标准化角色体系,明确专职临床试验药师的核心权责,利用
          前沿技术为专职临床试验药师角色的发挥提供全方位支撑等措施,充分发挥其药学专业优势,助力抗肿瘤新药研发流程的规范化
          与高效化。
          关键词  专职临床试验药师;早期临床试验;抗肿瘤药物;角色定位;药学服务

          Study  on  the  role  definition  of  full-time  pharmacists  in  the  management  of  early-phase  clinical  trials  of
          antineoplastic drugs
          ZHAO Juan,GONG Li,SHEN Jie,YANG Huiyao,LIAO Bin(Phase  Ⅰ  Clinical  Ward,  Chongqing  University
          Cancer Hospital, Chongqing 400030, China)

          ABSTRACT     OBJECTIVE To clarify the roles and functions of full-time pharmacists in the management of early-phase clinical
          trials of antineoplastic drugs, and to provide theoretical and practical support for their transformation from traditional drug managers
          to multi-dimensional roles in clinical research. METHODS  Combined with relevant regulations such as the Good Clinical Practice
         (GCP) (2020  Edition),  and  based  on  the  clinical  practice  experience  of  the  Phase  Ⅰ  Clinical  Ward  in  our  hospital,  this  study
          systematically  sorted  out  full-time  pharmacists’  roles  and  functions  in  early-phase  clinical  trials  of  antineoplastic  drugs,  and
          explored  the  core  challenges  and  optimization  pathways  for  role  transformation  and  capacity-building  of  domestic  full-time  clinical
          trial  pharmacists.  RESULTS  &  CONCLUSIONS  Full-time  pharmacists  assumed  multiple  roles  in  early-phase  clinical  trials  of
          antineoplastic  drugs,  including  providing  pharmaceutical  support  for  protocol  design,  implementing  whole-process  standardized
          management  of  clinical  trial  drugs,  ensuring  medication  safety  for  clinical  trial  subjects/participants,  conducting  quality  control
          throughout the clinical trial process, and serving as a bridge for interdisciplinary collaboration and communication. Currently, there
          are  challenges  in  this  field  in  China,  such  as  unclear  roles,  an  imperfect  capacity  building  system,  and  insufficient  regulatory
          support. This  paper  proposes  that  by  establishing  a  standardized  role  framework,  clarifying  the  core  responsibilities  and  authorities
          of  full-time  pharmacists,  and  leveraging  cutting-edge  technologies  to  provide  comprehensive  support  for  their  roles,  so  as  to  fully
          harness  their  pharmaceutical  expertise  and  contribute  to  the  standardization  and  efficiency  of  the  antineoplastic  new  drug
          development process.
          KEYWORDS     full-time pharmacist; early-phase clinical trial; antineoplastic drugs; role definition; pharmaceutical care


                                                                  抗肿瘤药物临床试验在全球药物研发中占据核心

              Δ 基金项目 重庆市沙坪坝区技术创新项目(No.2025098)                地位。据统计,2024 年全球共启动了 2 162 项肿瘤学临
             *第一作者 主管药师,硕士。研究方向:药物临床试验。E-mail:                床试验,占所有临床试验的41%,较2019年增长12%,较
          ZJde2021@163.com
                                                                               [1]
                                                              10 年前则增长 58% 。其中,Ⅰ期抗肿瘤临床试验占
              # 通信作者 副主任药师,硕士。研究方向:药物临床试验。
                                                                 [1]
          E-mail:liaobin2011@163.com                          38% ,表明抗肿瘤药物早期临床试验在新药研发中有
          · 294 ·    China Pharmacy  2026 Vol. 37  No. 3                               中国药房  2026年第37卷第3期
   23   24   25   26   27   28   29   30   31   32   33